<DOC>
	<DOC>NCT01539681</DOC>
	<brief_summary>Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.</brief_summary>
	<brief_title>Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients with histologically/cytologically confirmed HCC or radiographically diagnosed as per AASLD criteria, who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made Patients must have signed the informed consent form Patients must have a life expectancy of at least 8 weeks Inclusion criteria must follow the approved local product information. Prior treatment with sorafenib Concomitant participation in other clinical studies Exclusion criteria must follow the approved local product information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Cancer, Liver</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
</DOC>